



ANTIBIOTIC RESISTANCE PATTERN AND PLASMID PROFILING OF PSEUDOMONAS AERUGINOSA ISOLATED FROM ICU PATIENTS

Bushra Adeel^{1*}, Atta urrehman², Fazal ur Rehman³, Akhtar Hamid Tariq⁴, Muhammad Mazhar⁵, Amjad Iqbal Burq⁶, Farah Naz Tahir⁷,

^{1*}MBBS, Mphil Microbiology, Associate Professor Pathology, Rashid Latif Medical College, bushraadeel@gmail.com

²Post graduate resident in internal medicine. DHQ hospital Dera Ismail Khan. attackundi899123@gmail.com

³Assistant Professor Pathology (Microbiology), Pathology Department, Loralai Medical College Loralai, Email: drfazalkakar@gmail.com

⁴Associate Professor Pathology, (Chemical Pathology), Pathology Department, Loralai Medical College Loralai, Email: Akhtarhamid91@gmail.com

⁵Assistant Professor Pathology (Microbiology), Pathology Department Loralai Medical College Loralai, Email: muhammadmazhar772@gmail.com

⁶Associate Professor, Community Medicine, Islam Medical College, Sialkot, amjadburq@gmail.com

⁷MBBS, MPhil, PhD, Associate Professor of Biochemistry, Central Park Medical College, Lahore Pakistan, tahirnazfarah@gmail.com

***Corresponding author:** Bushra Adeel
bushraadeel@gmail.com

Abstract

Pseudomonas aeruginosa remains a formidable nosocomial pathogen, particularly in intensive care units (ICUs), due to its intrinsic resistance mechanisms and capacity to acquire additional resistance determinants. This study aimed to elucidate the antibiotic resistance patterns and plasmid profiles of *P. aeruginosa* isolates obtained from ICU patients in Lahore, Pakistan, thereby contributing novel insights into the regional epidemiology of this pathogen. A total of 29 non-duplicate clinical isolates were collected over a 12-month period and subjected to antimicrobial susceptibility testing and plasmid profiling. The findings revealed a high prevalence of multidrug-resistant (MDR) strains, with significant resistance observed against carbapenems and fluoroquinolones. Plasmid analysis identified the presence of resistance genes, including bla_{NDM-1} and bla_{OXA-48}, underscoring the role of plasmid-mediated gene transfer in the dissemination of resistance. Statistical analysis demonstrated a significant association between prior antibiotic use and the emergence of MDR strains ($p < 0.05$). These results highlight the urgent need for stringent antibiotic stewardship and infection control measures to curb the spread of resistant *P. aeruginosa* in ICU settings. This study fills a critical gap in the understanding of resistance mechanisms in *P. aeruginosa* within the Pakistani healthcare context and sets the stage for future research into targeted therapeutic strategies.

Keywords: *Pseudomonas aeruginosa*, antibiotic resistance, plasmid profiling

Introduction

Pseudomonas aeruginosa is a ubiquitous and highly versatile pathogen, often associated with healthcare-associated infections, particularly in critically ill patients. It is an opportunistic pathogen responsible for a wide array of infections, including pneumonia, urinary tract infections, bacteremia, and wound infections. In the context of intensive care units (ICUs), where patients are often immunocompromised and undergo invasive procedures, *P. aeruginosa* represents a significant threat due to its multidrug resistance (MDR) profile and capacity to persist in hospital environments. The emergence of resistance among *P. aeruginosa* strains poses a severe challenge to treatment, as it limits the available therapeutic options, leading to prolonged hospital stays, increased healthcare costs, and higher mortality rates.¹⁻³

Antibiotic resistance in *P. aeruginosa* is multifactorial, involving intrinsic mechanisms such as efflux pumps, altered penicillin-binding proteins, and impermeable outer membranes, as well as acquired resistance through horizontal gene transfer. One key mechanism of acquired resistance is plasmid-mediated gene transfer, where resistance genes are transferred between bacteria, further complicating treatment options. In ICU settings, the frequent use of broad-spectrum antibiotics, combined with the potential for cross-transmission between patients, creates an environment conducive to the selection and spread of resistant strains. Understanding the antibiotic resistance patterns and the genetic mechanisms behind these resistances is crucial for developing effective treatment strategies and infection control measures.⁴⁻⁷

Recent studies have demonstrated that *P. aeruginosa* exhibits significant resistance to commonly used antibiotics, including beta-lactams, aminoglycosides, and fluoroquinolones. Carbapenem-resistant *P. aeruginosa*, in particular, has become an alarming clinical concern worldwide, with the spread of carbapenemases such as New Delhi metallo-beta-lactamase (NDM) and oxacillinases (OXA) further complicating treatment. These enzymes, often encoded by plasmids, confer resistance to a broad range of beta-lactam antibiotics, rendering many treatment regimens ineffective. Moreover, the acquisition of resistance determinants, including those for aminoglycosides and fluoroquinolones, poses a serious challenge to clinicians managing ICU patients.⁸⁻¹¹

Plasmid profiling offers valuable insights into the genetic basis of antibiotic resistance by identifying the presence of plasmids that harbor resistance genes. This technique has been widely used to investigate the clonal spread of resistant strains and the role of horizontal gene transfer in resistance dissemination. However, data regarding the plasmid profiles of *P. aeruginosa* isolates from ICU patients in many regions, including Pakistan, remain limited. This gap in knowledge highlights the need for further studies to explore the genetic mechanisms underlying antibiotic resistance in *P. aeruginosa* and their clinical implications.¹²⁻¹³

The objective of this study was to investigate the antibiotic resistance patterns and plasmid profiles of *P. aeruginosa* isolates from ICU patients. This research aims to provide a comprehensive understanding of the prevalence of multidrug-resistant strains, identify plasmid-mediated resistance mechanisms, and assess the association between antibiotic use and resistance patterns. Additionally, the study intends to highlight potential risk factors for the acquisition of resistant strains and propose strategies for improving infection control practices in ICU settings.

Methodology

A total of 29 non-duplicate clinical isolates of *P. aeruginosa* were obtained from ICU patients at a Rashid Latif Medical College in Lahore, Pakistan, over a period of 12 months (January to December 2024). The isolates were collected from various clinical samples, including blood, urine, sputum, and wound swabs, from patients who had been admitted to the ICU and had received antibiotics prior to sample collection.

For the identification of *P. aeruginosa*, standard microbiological methods, including Gram staining, oxidase test, and biochemical testing, were used. The confirmation of *P. aeruginosa* was further validated by molecular techniques, such as the amplification of the 16S rRNA gene.

Antimicrobial susceptibility testing was performed using the Kirby-Bauer disk diffusion method, in accordance with the Clinical and Laboratory Standards Institute (CLSI) guidelines. The antibiotics

tested included amikacin, piperacillin-tazobactam, ciprofloxacin, meropenem, and colistin. The minimum inhibitory concentration (MIC) for meropenem and ciprofloxacin was determined using the E-test method.

Plasmid profiling was carried out by isolating plasmid DNA using a commercial plasmid extraction kit. The presence of plasmid bands was visualized on an agarose gel electrophoresis system. Plasmid-mediated resistance genes, such as bla_{NDM}-1, bla_{OXA}-48, and others associated with beta-lactam and aminoglycoside resistance, were detected by PCR amplification.

Statistical analysis was conducted using SPSS version 25.0. The sample size was calculated using Epi Info software, with an assumed prevalence of resistance of 50% and a confidence level of 95%. A sample size of 29 was determined to provide adequate power for the analysis. Continuous variables were presented as mean \pm standard deviation (SD), and categorical variables were expressed as frequencies and percentages. The chi-square test was used to determine the association between antibiotic use and the emergence of multidrug-resistant strains, with a p-value of < 0.05 considered statistically significant.

Results

The 29 *P. aeruginosa* isolates exhibited significant resistance to several commonly used antibiotics. The resistance rates for meropenem, ciprofloxacin, and amikacin were 72%, 65%, and 48%, respectively. The results revealed a high prevalence of multidrug-resistant strains, with 21 (72%) of the isolates classified as multidrug-resistant (MDR). The presence of plasmids was detected in 25 (86%) of the isolates, and plasmid profiling identified the presence of resistance genes, including bla_{NDM}-1 (n = 12) and bla_{OXA}-48 (n = 8), in several isolates.

The statistical analysis showed a significant association between prior antibiotic use and the emergence of MDR strains (p = 0.03), highlighting the role of selective pressure in the development of resistance. Patients who had received broad-spectrum antibiotics, such as carbapenems and fluoroquinolones, were more likely to harbor MDR strains.

Demographic Data Table

Demographic Factor	Total (n=29)	MDR (n=21)	Non-MDR (n=8)
Age (years)	45 \pm 12	47 \pm 11	42 \pm 13
Gender (Male/Female)	18/11	14/7	4/4
Previous Antibiotic Use	26 (90%)	19 (90%)	7 (87%)
Length of ICU Stay (days)	7 \pm 4	8 \pm 5	6 \pm 3

Table 2: Antibiotic Resistance Rates

Antibiotic	Resistance Rate (%)	p-value
Meropenem	72	0.03
Ciprofloxacin	65	0.04
Amikacin	48	0.02
Piperacillin-Tazobactam	38	0.05

Table 3: Plasmid Profile and Resistance Genes

Plasmid Profile	Resistance Genes (n)	Percentage (%)
bla_NDM-1	12	41.4
bla_OXA-48	8	27.6
No Plasmids	4	13.8

Discussion

The findings of this study underscore the rising threat posed by multidrug-resistant *P. aeruginosa* in ICU settings, a critical concern for infection control and patient management. The high resistance rates observed in this study, particularly to carbapenems and fluoroquinolones, are consistent with trends reported globally, highlighting the urgent need for more effective therapeutic interventions and preventive strategies. The detection of plasmid-mediated resistance genes, particularly bla_NDM-1 and bla_OXA-48, points to the significant role of horizontal gene transfer in the dissemination of resistance among clinical isolates.¹⁴⁻¹⁶

These results also support the hypothesis that prior antibiotic use contributes to the selection of MDR strains. The significant association between antibiotic exposure and the emergence of resistant strains suggests that restrictive antibiotic policies, alongside effective stewardship programs, could mitigate the spread of resistance. Furthermore, the high frequency of plasmids in MDR isolates emphasizes the importance of genetic mobility in the dissemination of resistance determinants. These findings align with other recent studies, reinforcing the notion that plasmid-mediated resistance is a key mechanism driving the persistence of MDR *P. aeruginosa* in hospital environments.¹⁷⁻²⁰

Plasmid profiling has proven to be an invaluable tool in understanding the genetic landscape of resistant *P. aeruginosa*. The identification of specific resistance genes, such as bla_NDM-1 and bla_OXA-48, offers valuable insight into the molecular mechanisms underlying resistance and aids in the design of targeted interventions. It is also important to consider the clinical implications of plasmid-mediated resistance, as these plasmids may facilitate the transfer of resistance genes to other pathogens, further exacerbating the global antibiotic resistance crisis.²¹⁻²⁵

This study also highlights the critical role of infection control practices in curbing the spread of MDR strains. Measures such as stringent hand hygiene, isolation of infected patients, and environmental cleaning are essential in preventing cross-transmission. Moreover, the implementation of molecular surveillance systems to track resistance patterns could improve the early detection of outbreaks and facilitate timely interventions.

In conclusion, the findings from this study contribute to the growing body of evidence on the epidemiology of MDR *P. aeruginosa* in ICU settings, emphasizing the importance of continuous monitoring and the need for a multifaceted approach to combating antibiotic resistance. Future studies should focus on exploring alternative therapeutic options, such as bacteriophage therapy or novel antibiotics, to combat the rising tide of resistance. Moreover, research into the molecular mechanisms of resistance, including the role of plasmid-mediated gene transfer, will be crucial in developing strategies to prevent the spread of resistant pathogens.

Conclusion

This study provides valuable insights into the antibiotic resistance patterns and plasmid profiles of *P. aeruginosa* isolates from ICU patients. The high prevalence of multidrug-resistant strains, combined with the presence of plasmid-mediated resistance genes, underscores the need for enhanced infection control and antibiotic stewardship in hospital settings. Further research is necessary to explore alternative treatment strategies and to better understand the genetic mechanisms driving resistance.

References

1. Kablak-Ziembicka A, Przewlocki T. Clinical significance of carotid intima-media complex and carotid plaque assessment by ultrasound for the prediction of adverse cardiovascular events in

- primary and secondary care patients. *J Clin Med.* 2021;10(20):4628. DOI: <https://doi.org/10.3390/jcm10204628>
2. Liu X, Zhang J, Li H, et al. Global prevalence of carbapenem-resistant *Pseudomonas aeruginosa* and molecular mechanisms involved: a systematic review. *J Glob Antimicrob Resist.* 2022;29:79-86. DOI: <https://doi.org/10.1016/j.jgar.2021.12.009>
 3. Shakil S, Haq ZU, Mehmood K, et al. Antimicrobial resistance of *Pseudomonas aeruginosa* in intensive care unit patients in a teaching hospital. *Am J Infect Control.* 2023;51(3):301-307. DOI: <https://doi.org/10.1016/j.ajic.2022.12.001>
 4. Martínez JL, Rojo F. Metabolism and fitness of *Pseudomonas aeruginosa* in the environment. *Microb Biotechnol.* 2021;14(3):618-634. DOI: <https://doi.org/10.1111/1751-7915.13757>
 5. Kumar V, Singhal L, Verma V. Epidemiology of carbapenem-resistant *Pseudomonas aeruginosa* isolates from a tertiary care hospital in India. *J Med Microbiol.* 2022;71(1):31-39. DOI: <https://doi.org/10.1099/jmm.0.001298>
 6. Jahan M, Ali S, Hamid A, et al. Plasmid-mediated resistance and its molecular mechanisms in *Pseudomonas aeruginosa* isolates. *J Antimicrob Chemother.* 2022;77(6):1663-1670. DOI: <https://doi.org/10.1093/jac/dkac040>
 7. Mazhar S, Rafique A, Aziz M. Antibiotic resistance patterns in *Pseudomonas aeruginosa* isolates from patients in intensive care units. *Int J Antimicrob Agents.* 2023;62(5):106937. DOI: <https://doi.org/10.1016/j.ijantimicag.2023.106937>
 8. Chatterjee A, Banerjee S, Saha B, et al. Molecular analysis of *Pseudomonas aeruginosa* resistance to beta-lactam antibiotics in hospital-associated infections. *J Clin Microbiol.* 2022;60(3):e01745-21. DOI: <https://doi.org/10.1128/JCM.01745-21>
 9. Adams MD, Beanan MJ, Yates L, et al. Whole-genome sequencing of *Pseudomonas aeruginosa* isolates from cystic fibrosis patients and their role in antimicrobial resistance. *Antimicrob Agents Chemother.* 2023;67(4):e01969-22. DOI: <https://doi.org/10.1128/AAC.01969-22>
 10. Begum F, Rana MS, Azam S. Plasmid-mediated resistance in *Pseudomonas aeruginosa* isolated from different clinical sources. *Infect Drug Resist.* 2022;15:2173-2181. DOI: <https://doi.org/10.2147/IDR.S358487>
 11. Hassan I, Nazir R, Rauf A, et al. Epidemiology and molecular characterization of multidrug-resistant *Pseudomonas aeruginosa* in Pakistan. *BMC Infect Dis.* 2021;21(1):413. DOI: <https://doi.org/10.1186/s12879-021-06065-4>
 12. Liu Y, Wang R, Liu Z, et al. Mechanisms of carbapenem resistance in *Pseudomonas aeruginosa* and the role of mobile genetic elements. *Front Microbiol.* 2021;12:739149. DOI: <https://doi.org/10.3389/fmicb.2021.739149>
 13. Shams M, Zaki M, Ameen S. Clonal spread of multidrug-resistant *Pseudomonas aeruginosa* in the intensive care unit: Role of plasmids and horizontal gene transfer. *J Infect Public Health.* 2023;16(1):122-128. DOI: <https://doi.org/10.1016/j.jiph.2022.05.017>
 14. Alene KA, Yusuf A, Woldeamanuel Y, et al. Global burden of carbapenem-resistant *Pseudomonas aeruginosa* infections: Systematic review and meta-analysis. *PLoS One.* 2022;17(1):e0261245. DOI: <https://doi.org/10.1371/journal.pone.0261245>
 15. Fadaei R, Zong Z, Li W, et al. Evaluation of antibiotic resistance mechanisms in *Pseudomonas aeruginosa* isolated from ICU patients. *J Antimicrob Chemother.* 2022;77(5):1184-1190. DOI: <https://doi.org/10.1093/jac/dkab514>
 16. Khan MA, Shahzad M, Aslam B, et al. Molecular and epidemiological investigation of *Pseudomonas aeruginosa* in hospital settings: A focus on plasmid-mediated resistance. *Microorganisms.* 2021;9(4):782. DOI: <https://doi.org/10.3390/microorganisms9040782>
 17. Kaur N, Verma P, Sood S, et al. Plasmid profiling and antibiotic susceptibility patterns of *Pseudomonas aeruginosa* isolated from various clinical specimens. *J Infect Chemother.* 2022;28(7):898-904. DOI: <https://doi.org/10.1016/j.jiac.2022.03.004>
 18. Yilmaz M, Gülmez D, Dönmez S, et al. Investigation of *Pseudomonas aeruginosa* resistance to antibiotics and the role of efflux pumps in resistance mechanisms. *Clin Microbiol Infect.* 2022;28(2):214-222. DOI: <https://doi.org/10.1016/j.cmi.2021.09.004>

19. Taneja N, Mishra A, Tiwari S. Comparative study of carbapenem resistance in *Pseudomonas aeruginosa* and its association with plasmid-borne resistance genes. *Antimicrob Agents Chemother*. 2021;65(12):e01756-21. DOI: <https://doi.org/10.1128/AAC.01756-21>
20. Muhammad I, Khan M, Arshad N. Prevalence of multi-drug resistant *Pseudomonas aeruginosa* in hospitalized patients in Pakistan. *J Coll Physicians Surg Pak*. 2023;33(2):116-120. DOI: <https://doi.org/10.29271/jcpsp.2023.02.116>
21. Silva DC, Cardoso PF, Souza GC, et al. Antimicrobial resistance of *Pseudomonas aeruginosa* in nosocomial infections in Brazilian hospitals: Molecular characterization of resistance mechanisms. *Front Microbiol*. 2023;14:773462. DOI: <https://doi.org/10.3389/fmicb.2023.773462>
22. Gupta A, Kumar A, Bhattacharya D, et al. Role of plasmids in the spread of *Pseudomonas aeruginosa* resistance in clinical isolates: A hospital-based study. *Microb Drug Resist*. 2022;28(1):29-37. DOI: <https://doi.org/10.1089/mdr.2021.0169>
23. Tahir A, Tariq A, Yasmin R. Antibiotic resistance patterns and plasmid profiling of *Pseudomonas aeruginosa* from ICU patients. *Infect Control Hosp Epidemiol*. 2021;42(10):1231-1237. DOI: <https://doi.org/10.1017/ice.2021.1839>
24. Ahmed M, Zafar A, Niazi M. Surveillance of multi-drug resistant *Pseudomonas aeruginosa* in a tertiary hospital in Pakistan and plasmid-based resistance characterization. *BMC Microbiol*. 2022;22(1):97. DOI: <https://doi.org/10.1186/s12866-022-02107-w>
25. Mondal K, Tiwari D, Singh D, et al. Characterization of *Pseudomonas aeruginosa* resistance in intensive care units: A comprehensive molecular approach. *J Med Microbiol*. 2023;72(3):182-190. DOI: <https://doi.org/10.1099/jmm.0.001562>